Insulin polysialic (Xenetic Biosciences)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin polysialic (Xenetic Biosciences)
Drug Alias NameRecombinant human insulin (Xenetic Biosciences)Polysialylated insulinPolysialic insulinSuliXenSYN-20090110-RU +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonistsOrnithine decarboxylase stimulantsPhosphokinases stimulants
TargetsInsulin receptorOrnithine decarboxylasePhosphokinases
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Central Nervous System Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLipoxen Technologies Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLipoxen Technologies LtdSynbioXenetic Biosciences Inc
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Central Nervous System Diseases

Other Information

ATC CodeN/A
Related LinksN/A